You are here:

darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Symtuza)

Advice

following an abbreviated submission

darunavir, cobicistat, emtricitabine, tenofovir alafenamide (Symtuza®) is accepted for use within NHS Scotland.

Indication under review: the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).  

SMC has previously accepted darunavir/cobicistat (Rezolsta®) and emtrictabine/tenofovir alafenamide (Descovy®). Symtuza® (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) provides a single-tablet alternative to Rezolsta® plus Descovy® at no additional cost.

Drug Details

Drug Name: darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Symtuza)
SMC Drug ID: 1290/18
Manufacturer: Janssen-Cilag Ltd
Indication: The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 15 January 2018

Back